Drug Development for COVID-19
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Drug Discovery, Development and Delivery".
Deadline for manuscript submissions: closed (15 December 2021) | Viewed by 22407
Special Issue Editor
Special Issue Information
Dear Colleagues,
The recent pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) poses a serious threat to human health and the global economy. Vaccination can significantly reduce the severe cases and death rate; however, effective therapeutics for COVID-19 are urgently needed, especially in the context of rapid virus evolution. Neutralising antibodies can be useful with high cost. Repurposed small molecule drugs like remdesivir and dexamethasone could have modest effects in moderate to severe cases. The development of effective virus-specific small molecules drugs remains a challenge, despite a lot of progress being made. Viral protease, RNA polymerase and spike proteins provide good targets for drug development. Host response modulators are also important for disease treatment. With high-throughput assays, an ample amount of high resolution structures and modern computer-aided drug design, rapid progress can be made.
Dr. Yuguang Zhao
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- vaccine
- antibodies, nanobodies and other macromolecules
- drug repurposing
- virla protease inhibitors
- viral RNA polymerase inhibitors
- spike/RBD interacting molecules
- host response modulators